glp-1-based therapy Rethinking GLP-1RA Through the Lens of Glucagon and Resilience Trial suggests GLP-1 combo therapy

Broader intermittent fasting protocols achieve 3 to 8 percent weight loss over 6 to 12 months

Hair loss associated with GLP-1 medications is generally related to rapid weight loss rather than the medication itself

Mounjaro: An FDA-approved branded medication containing tirzepatide, primarily for type 2 diabetes, also widely recognized for its significant weight loss benefits

Meaningful weight loss typically occurs gradually, and the most significant results often take time to develop

Access this article Similar content being viewed by others References International Diabetes Federation

The Wegovy pill (25 mg) produces an average weight loss of 13.6% in 64 weeks (about a year and three months), according to a study of adults with obesity or overweight